This is a summary of the European public assessment report (EPAR) for Alprolix. It explains how the Agency assessed the medicine to recommend its authorisation in the EU and its conditions of use. It is not intended to provide practical advice on how to use Alprolix. For practical information about using Alprolix, patients should read the package leaflet or contact their doctor or pharmacist.
Therapeutic Indication
### Therapeutic indication Treatment and prophylaxis of bleeding in patients with haemophilia B (congenital factor IX deficiency).
Therapeutic Area (MeSH)
N/AATC Code
B02BD04
ATC Item
coagulation factor IX
Pharmacotherapeutic Group
N/A
Active Substance (Summary)
INN / Common Names
N/A| Substance | CAS | Monograph |
|---|---|---|
| eftrenonacog alfa | N/A | 艾诺凝血素α |
EMA Name
Alprolix
Medicine Name
Alprolix
Aliases
N/ANo risk management plan link.
